Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Common Equity (2016 - 2023)

Rapid Therapeutic Science Laboratories' Common Equity history spans 8 years, with the latest figure at -$2.7 million for Q2 2023.

  • For Q2 2023, Common Equity rose 6.17% year-over-year to -$2.7 million; the TTM value through Jun 2023 reached -$2.7 million, up 6.17%, while the annual FY2022 figure was -$3.1 million, 127.35% down from the prior year.
  • Common Equity for Q2 2023 was -$2.7 million at Rapid Therapeutic Science Laboratories, up from -$2.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $877380.0 in Q1 2021 and bottomed at -$3.3 million in Q3 2019.
  • The 5-year median for Common Equity is -$2.1 million (2021), against an average of -$1.8 million.
  • The largest YoY upside for Common Equity was 164.3% in 2021 against a maximum downside of 12240.42% in 2021.
  • A 5-year view of Common Equity shows it stood at -$1.4 million in 2019, then surged by 99.18% to -$11197.0 in 2020, then tumbled by 12240.42% to -$1.4 million in 2021, then plummeted by 127.35% to -$3.1 million in 2022, then rose by 12.81% to -$2.7 million in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Common Equity are -$2.7 million (Q2 2023), -$2.8 million (Q1 2023), and -$3.1 million (Q4 2022).